Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.53 |
| ▸ | USP30 | Q70CQ3 | 7/20 | 0.53 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 3/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.45 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.45 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.45 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.45 |
| ▸ | TDO2 | P48775 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4053814 | 0.88 | USP30 (0.51) | USP30AURKAGABRA1GABRG2GABRB3 | |
| SCHEMBL4050578 | 0.85 | AURKA (0.53) | GSK3BUSP30PIN1AURKACLK4 | |
| SCHEMBL4059131 | 0.83 | AURKA (0.56) | GSK3BUSP30AURKACLK4 | |
| SCHEMBL4058832 | 0.83 | AURKA (0.46) | GSK3BUSP30PIN1AURKACLK4 | |
| SCHEMBL4061926 | 0.83 | GUSB (0.48) | USP30AURKA | |
| SCHEMBL4051344 | 0.82 | USP30 (0.47) | GSK3BUSP30PIN1AURKAGABRA1 | |
| SCHEMBL4061906 | 0.81 | MGAM (0.51) | PIN1AURKA | |
| SCHEMBL4058688 | 0.80 | AURKA (0.58) | USP30AURKA | |
| SCHEMBL4050475 | 0.80 | NR1I3 (0.52) | USP30PIN1AURKA | |
| SCHEMBL4052742 | 0.80 | GUSB (0.52) | PIN1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622479-B2 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20050101647-A1 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1460067-A1 | BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101647-A1 | Bicyclic derivative, its production and use | ABL1, SRC, PTK2B | GSK3B 284/4885USP30 2997/4885PIN1 2626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.